-
Kitasamycin for Swine Dysentery: Evidence and Limits
2026-09-19
This study combines susceptibility testing, 23S rRNA mutation analysis, and a controlled pig challenge to evaluate kitasamycin against Brachyspira hyodysenteriae. Its main contribution is showing that prophylactic and therapeutic kitasamycin can prevent clinical swine dysentery when the infecting isolate remains susceptible, while also highlighting the limitations imposed by widespread macrolide resistance.
-
Proteasome Controls for Lactylation-Driven Cancer Biology
2026-09-19
A translational framework for using (R)-MG132 as a stereochemically matched negative control when testing whether proteasome activity contributes to HNRNPU K181 lactylation, PHGDH regulation, and serine-metabolic rewiring in cervical cancer.
-
Macrophage EV miR-660 in Breast Cancer Metastasis
2026-09-18
The reference study identifies a macrophage-to-tumor communication mechanism in which extracellular-vesicle-shuttled miR-660 suppresses KLHL21 and activates the IKKβ/NF-κB p65 axis. Its integrated tissue, cell, molecular, and mouse-model experiments connect tumor-associated macrophage signaling with breast cancer invasion and metastatic dissemination.
-
Etomoxir for Fatty Acid Oxidation Research
2026-09-18
Etomoxir enables controlled disruption of mitochondrial fatty acid oxidation in cardiac, immune, and neuroinflammatory models. This practical guide combines concentration-aware assay design with standardized whole-blood stimulation, lipid readouts, and troubleshooting strategies that help separate CPT-1 effects from DGAT-related confounding.
-
BMS 309403: A Mechanism-First Research Guide
2026-09-17
BMS 309403 is a potent FABP4 inhibitor for dissecting lipid handling, macrophage inflammation, and foam-cell formation. This mechanism-first guide translates recent SERCA2–calcineurin–FoxO1–FABP4 findings into practical assay decisions for cardiovascular and metabolic research.
-
740 Y-P: Practical PI 3-Kinase Activation Guide
2026-09-17
740 Y-P is a cell-permeable PI 3-kinase activator for controlled PI3K/AKT pathway modulation in biochemical and cellular assays. This guide covers preparation, controls, storage, and interpretation for vesicular trafficking research, cancer research, neuronal cell survival, and apoptosis assays; it is not a recommendation for in vivo use.
-
Wortmannin: Reading PI3K Inhibition Correctly
2026-09-16
Wortmannin is a PI3K inhibitor whose irreversible pharmacology can clarify signaling, viral entry, and apoptosis assay results when concentration, timing, and orthogonal controls are aligned. This guide uses the grass carp reovirus study to show how to distinguish target biology from nonspecific pathway effects.
-
Esculetin Blocks CKLF1-Linked Neutrophil Infiltration
2026-09-15
This study identifies CKLF1-mediated neutrophil recruitment as a mechanistic link between post-stroke inflammation and impaired recovery. In a photothrombotic mouse model, esculetin reduced infarct burden, improved neurological behavior, and enhanced motor-network activity while suppressing the CKLF1/CCR5 axis, with genetic evidence that its efficacy depends on CKLF1-related signaling.
-
Bazedoxifene: Reliable ER Assay Workflows
2026-09-15
Learn how Bazedoxifene (SKU A3232) can improve the interpretation, handling, and reproducibility of estrogen-receptor-focused viability and proliferation assays. This scenario-based guide connects receptor pharmacology with practical stock preparation, controls, readout selection, and vendor evaluation.
-
Natural Compounds Against SARS-CoV-2: Docking Evidence
2026-09-14
This 2022 Journal of Molecular Modeling study introduced a dual-target computational strategy that screened vitamin-related natural compounds against both the SARS-CoV-2 spike receptor-binding domain and 3CL protease. Its prioritized candidates provide hypotheses for blocking viral entry and polyprotein processing, but the docking and molecular dynamics results require biochemical, cellular, and pharmacological validation.
-
Etoposide (VP-16) Workflow for DNA Damage Assays
2026-09-14
Build more informative cancer biology experiments with Etoposide (VP-16), from topoisomerase II inhibition and DNA double-strand break measurement to apoptosis and viability profiling. This guide combines practical DMSO handling, dose–time design, troubleshooting, and translational context for reproducible cancer chemotherapy research.
-
Dabigatran Etexilate: Oral Direct Thrombin Inhibition
2026-09-13
The reference review presents dabigatran etexilate as the first oral direct thrombin inhibitor marketed in the United States, emphasizing its rapid, predictable anticoagulant activity and reduced dependence on routine coagulation monitoring. Its prodrug design, carboxylesterase-mediated activation, lack of cytochrome P450 involvement, renal dosing requirements, and evidence across venous thromboembolism and atrial fibrillation provide a framework for interpreting both its clinical value and its limitations.
-
Tamoxifen Workflows for CreER and Cancer Research
2026-09-12
Tamoxifen combines estrogen-receptor modulation with practical utility in inducible genetics, cancer-cell assays, and mechanism-focused screening. This workflow guide covers stock preparation, CreER-mediated gene knockout, assay controls, troubleshooting, and how a SERM repurposing study informs cross-domain experimental design.
-
1-methyl Adenosine: Assay Workflows
2026-09-11
Turn 1-methyl Adenosine from a modified nucleoside into both an experimental reagent and a measurable RNA-turnover endpoint. An isomer-resolved UHPLC–MS/MS strategy adds matrix control, sensitivity, and practical rigor for RNA modification research, cancer metabolism studies, and biomarker discovery.
-
Norepinephrine Bitartrate: From Dose to Design
2026-09-11
Norepinephrine bitartrate is more than a vasoconstrictor: it is a powerful tool for connecting receptor pharmacology with cardiovascular model design. This guide explains how salt form, exposure, assay context, and clinical conversion data should shape reproducible research workflows.